Related Experiment Videos
Liver and biliary problems in cystic fibrosis
C Colombo1, P M Battezzati, M Strazzabosco
1Department of Pediatrics, University of Sassari, Italy.
Seminars in Liver Disease
|October 17, 1998
Summary
Cystic fibrosis (CF) liver disease, affecting 17% of patients over 10 years, is a major complication. Early diagnosis and ursodeoxycholic acid treatment show promise for managing this inherited liver disorder.
Area of Science:
- Hepatology
- Gastroenterology
- Genetics
Background:
- Cystic fibrosis (CF) liver disease is increasingly diagnosed due to improved patient survival and hepatic assessment.
- It is a major CF complication impacting quality of life and survival.
- Considered the first inherited liver disorder linked to cholangiocyte transport defects.
Purpose of the Study:
- To investigate the incidence and characteristics of liver disease in cystic fibrosis patients.
- To evaluate the role of CFTR defects in biliary epithelium pathobiology.
- To assess the effectiveness of ursodeoxycholic acid in managing CF-associated liver disease.
Main Methods:
- Longitudinal follow-up of 173 cystic fibrosis patients.
- Analysis of cumulative incidence of liver disease over a mean of 10 years.
- Review of treatment outcomes with ursodeoxycholic acid.
Main Results:
- A cumulative incidence of 17% for liver disease was observed in CF patients over 10 years.
- Impaired biliary epithelium secretory function is implicated in CF liver disease pathogenesis.
- Ursodeoxycholic acid shows benefits in liver biochemistry and function, but long-term outcome data are lacking.
Conclusions:
- Early diagnosis and intervention are crucial for managing CF-associated liver disease.
- Ursodeoxycholic acid is a promising therapeutic approach, particularly in early disease stages.
- Further research is needed on long-term effectiveness of bile acid therapy on clinically relevant outcomes.